PMID: 2493762Apr 1, 1989Paper

Adverse hemodynamic and clinical effects of encainide in severe chronic heart failure

Annals of Internal Medicine
S S GottliebM Packer

Abstract

To evaluate the hemodynamic effects of the antiarrhythmic drug, encainide, in patients with severe chronic heart failure. Unblinded, before-after study. Referral center for patients with heart failure. Thirty patients with severe chronic heart failure and a left ventricular ejection fraction less than 40%. Invasive hemodynamic measurements were done (using a balloon-tipped thermodilution catheter) before and for 3 hours after a single oral dose of 50 mg of encainide. Ninety to one hundred and twenty minutes after its administration, encainide produced a significant deterioration in cardiac performance, as reflected by a fall in cardiac index from 2.3 to 1.8 L/min.m2 body surface (mean change 0.5 +/- 0.1; P less than 0.001), a fall in stroke work index from 26 to 18 g.m/m2 (mean change 8 +/- 2; P less than 0.001), and an increase in left ventricular filling pressure from 19 to 22 mm Hg (mean change 3 +/- 2; P less than 0.05). These deleterious hemodynamic effects were accompanied by worsening symptoms of heart failure in 8 of the 30 patients. Serum levels of encainide and its metabolites, O-desmethylencainide and 3-methoxy-O-desmethylencainide, were within the therapeutic range in most patients. Encainide can cause adverse hemod...Continue Reading

Citations

Nov 1, 1990·Journal of Clinical Pharmacology·C M Pratt, L Moye
Nov 1, 1990·Journal of Clinical Pharmacology·P J Podrid
Nov 1, 1991·Journal of Clinical Pharmacology·H FruminN Kerin
Jul 1, 1994·Journal of Clinical Pharmacology·E G GiardinaR Sciacca
Jun 1, 1990·Cardiovascular Drugs and Therapy·M Sami
Aug 29, 1996·The American Journal of Cardiology·H L Greene
Apr 17, 2001·American Journal of Therapeutics·J C Somberg
Jan 1, 1997·Journal of Cardiovascular Electrophysiology·S N Singh
May 5, 2011·PloS One·Vasiliy GoralYe Fang
Oct 4, 2007·Journal of the American Geriatrics Society·Paul A Heidenreich, Gregg C Fonarow
Jan 16, 1990·The American Journal of Cardiology·C M Pratt, L A Moye
Nov 15, 1989·The American Journal of Cardiology·P J Podrid, F I Marcus
Jun 4, 1992·The American Journal of Cardiology·P J PodridT T Fuchs
Nov 1, 1989·American Heart Journal·S S Gottlieb
Feb 20, 1990·The American Journal of Cardiology·P J Podrid, S L Beau
Oct 1, 1993·Postgraduate Medicine·J B Conti, A B Curtis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.